Traci Lyons
Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Semaphorins | 9 | 2025 | 37 | 5.530 |
Why?
| | Breast Neoplasms | 26 | 2025 | 2382 | 4.660 |
Why?
| | Antigens, CD | 10 | 2025 | 558 | 4.660 |
Why?
| | Mammary Glands, Animal | 9 | 2025 | 128 | 2.540 |
Why?
| | Lymphatic Vessels | 6 | 2024 | 63 | 2.530 |
Why?
| | Mammary Glands, Human | 6 | 2024 | 68 | 2.450 |
Why?
| | Postpartum Period | 11 | 2022 | 373 | 2.110 |
Why?
| | Cyclooxygenase 2 | 6 | 2020 | 166 | 1.940 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 2 | 2025 | 61 | 1.360 |
Why?
| | Breast | 6 | 2024 | 156 | 1.320 |
Why?
| | Macrophages | 5 | 2025 | 1507 | 1.270 |
Why?
| | GPI-Linked Proteins | 8 | 2025 | 81 | 1.220 |
Why?
| | Carcinoma, Ductal, Breast | 2 | 2025 | 89 | 0.970 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2022 | 1443 | 0.940 |
Why?
| | Epithelial Cells | 4 | 2024 | 1131 | 0.930 |
Why?
| | Cell Line, Tumor | 14 | 2025 | 3542 | 0.910 |
Why?
| | Lymphangiogenesis | 4 | 2024 | 27 | 0.890 |
Why?
| | B7-H1 Antigen | 2 | 2025 | 244 | 0.870 |
Why?
| | Cell Plasticity | 1 | 2025 | 37 | 0.870 |
Why?
| | Tumor Microenvironment | 9 | 2025 | 734 | 0.830 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2025 | 177 | 0.830 |
Why?
| | Immune Tolerance | 1 | 2025 | 385 | 0.740 |
Why?
| | Puerperal Disorders | 2 | 2014 | 36 | 0.700 |
Why?
| | Receptors, Estrogen | 3 | 2021 | 401 | 0.700 |
Why?
| | Anoikis | 1 | 2021 | 31 | 0.690 |
Why?
| | Mammary Neoplasms, Animal | 3 | 2016 | 35 | 0.670 |
Why?
| | Mice | 21 | 2025 | 18329 | 0.650 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2020 | 193 | 0.650 |
Why?
| | Neoplasm Metastasis | 6 | 2025 | 688 | 0.640 |
Why?
| | Pregnancy Complications, Neoplastic | 4 | 2026 | 63 | 0.640 |
Why?
| | Extracellular Matrix | 5 | 2021 | 562 | 0.630 |
Why?
| | Animals | 26 | 2025 | 38030 | 0.560 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2021 | 881 | 0.550 |
Why?
| | Lactation | 4 | 2022 | 193 | 0.520 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 265 | 0.500 |
Why?
| | Neoplasm Invasiveness | 6 | 2025 | 506 | 0.500 |
Why?
| | NF-kappa B | 1 | 2019 | 666 | 0.470 |
Why?
| | Female | 31 | 2026 | 78844 | 0.450 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2021 | 440 | 0.430 |
Why?
| | Disease Models, Animal | 6 | 2025 | 4560 | 0.420 |
Why?
| | Aging | 1 | 2025 | 1969 | 0.420 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1321 | 0.410 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1149 | 0.400 |
Why?
| | Pregnancy | 11 | 2026 | 7202 | 0.390 |
Why?
| | Cell Movement | 6 | 2022 | 959 | 0.380 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2020 | 934 | 0.370 |
Why?
| | Carcinoma, Ductal | 1 | 2011 | 10 | 0.350 |
Why?
| | Fibrillar Collagens | 1 | 2011 | 14 | 0.350 |
Why?
| | Collagen | 3 | 2025 | 457 | 0.340 |
Why?
| | Mice, Knockout | 4 | 2025 | 3124 | 0.340 |
Why?
| | Humans | 34 | 2026 | 145474 | 0.330 |
Why?
| | Mice, Inbred BALB C | 3 | 2019 | 1261 | 0.320 |
Why?
| | Disease Progression | 4 | 2025 | 2864 | 0.300 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 2 | 2019 | 66 | 0.280 |
Why?
| | Cell Survival | 2 | 2021 | 1100 | 0.260 |
Why?
| | Membrane Glycoproteins | 2 | 2019 | 499 | 0.240 |
Why?
| | Signal Transduction | 6 | 2025 | 5216 | 0.230 |
Why?
| | Mice, SCID | 2 | 2020 | 369 | 0.230 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2021 | 337 | 0.230 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2007 | 192 | 0.230 |
Why?
| | Apoptosis | 2 | 2020 | 2440 | 0.230 |
Why?
| | Prognosis | 4 | 2020 | 4316 | 0.220 |
Why?
| | Mice, Inbred C57BL | 4 | 2021 | 5983 | 0.220 |
Why?
| | Mice, Inbred NOD | 3 | 2021 | 613 | 0.210 |
Why?
| | Chitin | 1 | 2024 | 9 | 0.210 |
Why?
| | Chitinases | 1 | 2024 | 9 | 0.210 |
Why?
| | Lymphatic System | 1 | 2024 | 15 | 0.210 |
Why?
| | Lymphatic Metastasis | 4 | 2024 | 331 | 0.200 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2025 | 219 | 0.200 |
Why?
| | Celecoxib | 2 | 2014 | 42 | 0.190 |
Why?
| | Biology | 1 | 2024 | 88 | 0.190 |
Why?
| | Head and Neck Neoplasms | 2 | 2020 | 561 | 0.190 |
Why?
| | Disease-Free Survival | 2 | 2021 | 767 | 0.180 |
Why?
| | Immune Evasion | 1 | 2022 | 61 | 0.180 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 17 | 0.180 |
Why?
| | Immunohistochemistry | 2 | 2019 | 1716 | 0.180 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 38 | 0.180 |
Why?
| | Integrin alpha6 | 1 | 2021 | 9 | 0.180 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 39 | 0.180 |
Why?
| | Caspase 7 | 1 | 2021 | 22 | 0.180 |
Why?
| | Integrin beta1 | 1 | 2021 | 33 | 0.170 |
Why?
| | Gene Knockdown Techniques | 2 | 2020 | 333 | 0.170 |
Why?
| | Melanoma, Experimental | 1 | 2022 | 109 | 0.170 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2024 | 218 | 0.170 |
Why?
| | Mammals | 1 | 2022 | 286 | 0.160 |
Why?
| | Fibronectins | 2 | 2020 | 136 | 0.160 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2020 | 35 | 0.160 |
Why?
| | Caspase 3 | 1 | 2021 | 242 | 0.160 |
Why?
| | Cytoskeletal Proteins | 1 | 2021 | 156 | 0.160 |
Why?
| | Actin Cytoskeleton | 1 | 2021 | 103 | 0.160 |
Why?
| | Hyaluronan Receptors | 1 | 2020 | 104 | 0.160 |
Why?
| | Enzyme Activation | 1 | 2021 | 762 | 0.150 |
Why?
| | Adipocytes | 1 | 2021 | 223 | 0.150 |
Why?
| | Models, Biological | 3 | 2019 | 1764 | 0.150 |
Why?
| | Maternal Age | 1 | 2020 | 128 | 0.150 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2022 | 231 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 2 | 2020 | 969 | 0.150 |
Why?
| | Estrogens | 2 | 2020 | 367 | 0.150 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 977 | 0.140 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2019 | 62 | 0.140 |
Why?
| | Genes, Reporter | 1 | 2019 | 277 | 0.140 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 886 | 0.140 |
Why?
| | Pyrazoles | 2 | 2014 | 517 | 0.140 |
Why?
| | Sulfonamides | 2 | 2014 | 583 | 0.140 |
Why?
| | Actins | 1 | 2021 | 425 | 0.140 |
Why?
| | Phosphorylation | 2 | 2021 | 1707 | 0.140 |
Why?
| | Crosses, Genetic | 1 | 2018 | 123 | 0.140 |
Why?
| | Integrins | 1 | 2018 | 90 | 0.130 |
Why?
| | Extracellular Vesicles | 1 | 2020 | 171 | 0.130 |
Why?
| | Cell Proliferation | 3 | 2020 | 2507 | 0.130 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1505 | 0.130 |
Why?
| | RNA, Small Interfering | 1 | 2020 | 637 | 0.130 |
Why?
| | Protein Binding | 2 | 2022 | 2238 | 0.130 |
Why?
| | Podosomes | 1 | 2016 | 4 | 0.120 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2016 | 45 | 0.120 |
Why?
| | Neoplasms | 2 | 2026 | 2906 | 0.120 |
Why?
| | Neoplastic Stem Cells | 1 | 2020 | 409 | 0.120 |
Why?
| | Genetic Pleiotropy | 1 | 2016 | 30 | 0.120 |
Why?
| | rab GTP-Binding Proteins | 1 | 2016 | 76 | 0.120 |
Why?
| | Survival Rate | 1 | 2020 | 2090 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 981 | 0.110 |
Why?
| | Melanoma | 1 | 2022 | 759 | 0.110 |
Why?
| | Phenotype | 2 | 2021 | 3155 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2022 | 849 | 0.100 |
Why?
| | Blotting, Western | 3 | 2011 | 1179 | 0.100 |
Why?
| | Dinoprostone | 1 | 2014 | 180 | 0.100 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2019 | 919 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2019 | 1140 | 0.090 |
Why?
| | Endothelial Cells | 1 | 2018 | 874 | 0.090 |
Why?
| | Drug Design | 1 | 2013 | 175 | 0.090 |
Why?
| | Adult | 7 | 2025 | 40777 | 0.090 |
Why?
| | Hematopoietic Stem Cells | 1 | 2015 | 435 | 0.090 |
Why?
| | Ibuprofen | 1 | 2011 | 87 | 0.080 |
Why?
| | Risk | 2 | 2013 | 919 | 0.080 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2011 | 325 | 0.080 |
Why?
| | Time Factors | 4 | 2020 | 7123 | 0.080 |
Why?
| | BRCA1 Protein | 1 | 2010 | 82 | 0.070 |
Why?
| | Cohort Studies | 1 | 2020 | 6013 | 0.070 |
Why?
| | Macrophage Activation | 1 | 2010 | 181 | 0.070 |
Why?
| | Analysis of Variance | 1 | 2011 | 1300 | 0.070 |
Why?
| | Mutation | 1 | 2019 | 4075 | 0.070 |
Why?
| | Stromal Cells | 1 | 2009 | 121 | 0.070 |
Why?
| | Incidence | 2 | 2020 | 2923 | 0.070 |
Why?
| | Tamoxifen | 1 | 2009 | 191 | 0.070 |
Why?
| | Extracellular Matrix Proteins | 1 | 2009 | 156 | 0.070 |
Why?
| | Gonadal Steroid Hormones | 1 | 2009 | 143 | 0.070 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2010 | 317 | 0.060 |
Why?
| | Restriction Mapping | 1 | 2007 | 81 | 0.060 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2009 | 376 | 0.060 |
Why?
| | Disease Susceptibility | 1 | 2009 | 344 | 0.060 |
Why?
| | Cloning, Molecular | 1 | 2007 | 538 | 0.060 |
Why?
| | Estradiol | 1 | 2010 | 515 | 0.060 |
Why?
| | Cell Line | 2 | 2010 | 2823 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 1 | 2007 | 666 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2020 | 382 | 0.050 |
Why?
| | Base Sequence | 1 | 2007 | 2170 | 0.050 |
Why?
| | Immunotherapy | 2 | 2022 | 666 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2883 | 0.050 |
Why?
| | Young Adult | 3 | 2020 | 14218 | 0.050 |
Why?
| | Cell Cycle Proteins | 2 | 2020 | 630 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2214 | 0.040 |
Why?
| | Stress Fibers | 1 | 2021 | 18 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2022 | 177 | 0.040 |
Why?
| | Focal Adhesions | 1 | 2021 | 47 | 0.040 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 1 | 2020 | 21 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2022 | 153 | 0.040 |
Why?
| | Tumor Burden | 1 | 2022 | 325 | 0.040 |
Why?
| | Feedback, Physiological | 1 | 2020 | 80 | 0.040 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2020 | 14 | 0.040 |
Why?
| | SOXB1 Transcription Factors | 1 | 2020 | 67 | 0.040 |
Why?
| | Kidney | 1 | 2007 | 1497 | 0.040 |
Why?
| | Cell Adhesion | 1 | 2020 | 451 | 0.040 |
Why?
| | Proteomics | 2 | 2020 | 1188 | 0.040 |
Why?
| | Cell Communication | 1 | 2020 | 328 | 0.040 |
Why?
| | Ki-67 Antigen | 1 | 2019 | 117 | 0.030 |
Why?
| | Parity | 1 | 2019 | 111 | 0.030 |
Why?
| | Survival Analysis | 1 | 2022 | 1374 | 0.030 |
Why?
| | Hyaluronic Acid | 1 | 2020 | 226 | 0.030 |
Why?
| | Rats | 3 | 2013 | 5584 | 0.030 |
Why?
| | Proteins | 1 | 2024 | 1023 | 0.030 |
Why?
| | Monocytes | 1 | 2020 | 539 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 425 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 441 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2016 | 56 | 0.030 |
Why?
| | Global Health | 1 | 2020 | 403 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2016 | 131 | 0.030 |
Why?
| | Breast Feeding | 1 | 2020 | 446 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2019 | 503 | 0.030 |
Why?
| | Protein Domains | 1 | 2016 | 311 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2019 | 1471 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 2010 | 2524 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1767 | 0.020 |
Why?
| | Bone Marrow | 1 | 2015 | 306 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3623 | 0.020 |
Why?
| | Cadherins | 1 | 2013 | 200 | 0.020 |
Why?
| | Risk Factors | 2 | 2019 | 10885 | 0.020 |
Why?
| | Liver | 1 | 2020 | 1896 | 0.020 |
Why?
| | Middle Aged | 3 | 2020 | 36215 | 0.020 |
Why?
| | MicroRNAs | 1 | 2016 | 686 | 0.020 |
Why?
| | Weaning | 1 | 2010 | 51 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2010 | 64 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2010 | 148 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2013 | 1327 | 0.020 |
Why?
| | Matrix Metalloproteinases | 1 | 2010 | 95 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1547 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 171 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2010 | 365 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2010 | 155 | 0.020 |
Why?
| | Species Specificity | 1 | 2010 | 546 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 143 | 0.020 |
Why?
| | Protein Transport | 1 | 2010 | 442 | 0.020 |
Why?
| | Biomarkers | 2 | 2010 | 4295 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2067 | 0.020 |
Why?
| | Mice, Nude | 1 | 2009 | 679 | 0.020 |
Why?
| | Cell Cycle | 1 | 2010 | 598 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2010 | 730 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1368 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2009 | 372 | 0.010 |
Why?
| | Fibroblasts | 1 | 2009 | 1025 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2010 | 4148 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 22529 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2013 | 17291 | 0.010 |
Why?
| | Male | 1 | 2020 | 72842 | 0.010 |
Why?
| | Aged | 1 | 2010 | 26153 | 0.000 |
Why?
|
|
Lyons's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|